July 21st 2025
Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.
Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer
View More
Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights
View More
Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
View More
Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
View More
Continuous Therapy Best in Newly Diagnosed Multiple Myeloma
June 3rd 2014Continuous therapy produces drastically better progression-free survival and overall survival outcomes in patients with multiple myeloma. A novel endpoint involving time to second progression is an important tool in evaluating this type of treatment in the future.
Atypical CML Distinct From Related Myelodysplastic/Myeloproliferative Disorders
May 7th 2014A rare subtype of disease known as atypical chronic myeloid leukemia (aCML) has been shown to be clinically distinct from a related condition known as unclassifiable myelodysplastic/myeloproliferative neoplasm.
Diffuse Large B-Cell Lymphoma: One Treatment No Longer Fits All
April 15th 2014Rationally designed clinical trials investigating novel agents in patient populations enriched for those who are most likely to benefit will be instrumental for expediting progress. With respect to DLBCL, it has become clear that one treatment no longer fits all.
Diffuse Large B-Cell Lymphoma: Changing Treatment Paradigms
April 15th 2014With the progress in diagnostic methods that has made it possible to decipher the genetic code of DLBCL within a relatively short time, and with the increasing number of drugs that are entering clinical trials, our next big challenge is to enroll patients in trials in a timely manner.
Appropriate Management of Molecular Subtypes of Diffuse Large B-Cell Lymphoma
April 15th 2014The classification of diffuse large B-cell lymphoma into three distinct molecular diseases--germinal center B-cell–like subtype, an activated B-cell–like subtype, and a primary mediastinal B-cell lymphoma subtype--has laid the foundation for the development of new agents and novel strategies that target individual subtypes.
Oral Metabolism Drug Active in Acute Myeloid Leukemia
April 7th 2014New trial results show that a novel, oral metabolic inhibitor has demonstrated early activity in relapsed or refractory acute myeloid leukemia (AML), according to data presented at the annual meeting of the American Association of Cancer Research.
Three-Drug Myeloma Combo Produces Response in Nearly Two-Thirds of Relapsed Patients
March 11th 2014The combination of bortezomib, lenalidomide, and dexamethasone resulted in a partial response or better in more than 60% of patients with relapsed or refractory multiple myeloma, according to results of a phase II trial.
Leukemia Risk for Children Near Power Lines?
February 28th 2014Contrary to some previous research as well as popular belief, living underneath or near to power lines as a child may not have any notable effect on childhood leukemia risk, according to a new case-control study conducted in the United Kingdom.
Inherited Risk Factor Found in One-Third of African Americans Multiple Myeloma Patients
February 6th 2014More than one-third of African American patients with monoclonal gammopathy of undetermined significance or multiple myeloma were found to have an inherited risk factor for the disease, according to the results of a European study.